Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar candidate to Simponi (golimumab). Golimumab, a human monoclonal antibody, inhibits the biological activity of tumor necrosis factor alpha (TNF-alpha). The originator product, Simponi, is approved in the U.S. for moderate to severe rheumatoid arthritis; active psoriatic arthritis; active ankylosing ...